A severe daily headache and visual symptoms in a young woman are never just stress. IIH is underdiagnosed, underestimated, and entirely treatable when caught before the vision is permanently affected.
Idiopathic intracranial hypertension (IIH), sometimes called pseudotumor cerebri, is a condition in which the pressure of the cerebrospinal fluid (CSF) surrounding the brain is elevated without an obvious cause such as a tumour or obstruction. The raised pressure pushes on the optic nerves from behind, causing them to swell. Left untreated, this swelling permanently damages the optic nerves and causes irreversible vision loss. The headaches are often severe and disabling. IIH predominantly affects overweight women of childbearing age, though it can occur in anyone.
What You Need to Know About IIH
- IIH causes raised pressure around the brain without a tumour or blockage. The exact mechanism is not fully understood
- The most important risk factor is excess weight, particularly recent weight gain. Weight loss is the most effective long-term treatment
- It causes swelling of both optic nerves (papilloedema), which if untreated leads to permanent visual field loss
- Headache is the most common symptom and is often the most disabling aspect of the condition
- Diagnosis requires a lumbar puncture to directly measure CSF pressure. There is no other reliable way to confirm it
- Most patients respond well to weight loss and acetazolamide, and vision can be fully preserved with appropriate management
Why IIH Damages Vision
The optic nerves travel from the back of each eye through a sheath of fluid that is continuous with the cerebrospinal fluid surrounding the brain. When CSF pressure rises, that pressure is transmitted directly along these sheaths and pushes against the back of each optic nerve head. The nerve fibres swell at the point where they exit the eye. This is papilloedema.
Papilloedema in IIH is bilateral, meaning both optic nerves are affected. This distinguishes it from optic neuritis, which typically affects one eye. The swelling itself doesn’t always cause immediate visual symptoms, but persistent or severe papilloedema gradually damages nerve fibres, leading to visual field loss that typically starts in the periphery and can progress to involve central vision if pressure is not controlled. Once established, this damage is irreversible.
Symptoms
Headache
Headache is present in over 90 percent of patients and is usually the dominant complaint. Daily or near-daily, often described as a pressure or throbbing behind the eyes or across the whole head, frequently worse in the morning or when lying down. It can be severe enough to derail work, relationships, and quality of life. The headache of IIH has no specific pattern that reliably distinguishes it from migraine or tension headache. That’s one reason the condition is frequently misdiagnosed for months, sometimes years, before someone thinks to check the optic nerves.
Visual symptoms
Transient visual obscurations are brief episodes, lasting seconds, in which vision dims or blacks out in one or both eyes, often triggered by changes in posture. These fleeting episodes are characteristic of raised intracranial pressure and should always prompt investigation. Double vision, usually from a sixth nerve palsy, can also occur. Pulsatile tinnitus, a whooshing sound in the ears in time with the heartbeat, is present in around 50 percent of patients and is a surprisingly specific symptom of IIH.
Visual field loss
Formal visual field testing often reveals an enlarged blind spot or peripheral field loss even when a patient reports no visual symptoms. The visual field loss in IIH tends to be gradual and peripheral, and the brain adapts to it without the patient noticing until it is well advanced. Regular visual field testing is essential in monitoring IIH, even when vision subjectively feels fine.
Diagnosis
Clinical assessment and imaging
IIH is a diagnosis of exclusion: other causes of raised intracranial pressure must be ruled out first. An MRI brain scan with MR venography is performed to exclude tumours, venous sinus thrombosis, hydrocephalus, and other structural causes. Characteristic MRI findings that support IIH include an empty sella, flattening of the posterior globes, and distension of the optic nerve sheaths. Blood tests screen for underlying causes including thyroid disease, anaemia, and certain medications known to cause raised intracranial pressure.
Lumbar puncture
A lumbar puncture confirms the diagnosis by directly measuring CSF opening pressure. In IIH, the pressure is elevated above 25 cmH2O in adults. The CSF composition is normal, distinguishing IIH from infection or inflammatory causes. The lumbar puncture also has a therapeutic role: removing CSF during the procedure provides temporary relief of headache and visual symptoms while longer-term treatments take effect.
Ophthalmological assessment
Ophthalmology is central to both the diagnosis and ongoing monitoring of IIH. The ophthalmologist documents the degree of papilloedema using fundus photography and OCT of the optic nerve head, establishes a baseline visual field, and monitors both for signs of progression or improvement with treatment. Even when the headache is well controlled, visual monitoring must continue because optic nerve damage can progress silently.
Treatment
Weight loss
Weight loss is the single most effective long-term treatment for IIH in overweight patients. A sustained reduction of 5 to 10 percent of body weight reduces intracranial pressure, improves papilloedema, relieves headache, and in many cases produces complete remission. The IIH Weight Trial showed that a very low calorie diet was as effective as acetazolamide in improving visual fields. Bariatric surgery produces the most sustained weight loss and is associated with remission in the majority of appropriately selected patients.
Acetazolamide
Acetazolamide reduces CSF production and is the first-line medication for IIH. Usually started alongside dietary intervention and titrated to the maximum tolerated dose. Common side effects include tingling in the hands and feet, increased urination, altered taste of carbonated drinks, and fatigue. Those who cannot tolerate acetazolamide can switch to topiramate, which has the added benefit of promoting weight loss in some patients.
Surgical options
When visual field loss is progressing despite medical treatment, or when presentation is severe with rapidly deteriorating vision, surgery is needed. Optic nerve sheath fenestration creates small windows in the sheath surrounding the optic nerve to decompress it directly, protecting vision without reducing intracranial pressure. CSF diversion procedures such as lumboperitoneal or ventriculoperitoneal shunts reduce intracranial pressure throughout and can relieve both visual and headache symptoms. Venous sinus stenting is an emerging treatment for IIH associated with venous sinus stenosis.
IIH and Headache: A Difficult Relationship
For many patients with IIH, headache is the most disabling part of the condition. It is also one of the hardest symptoms to treat, and it does not always correlate with intracranial pressure or papilloedema. Some patients have severe headache with relatively mild disc swelling. Others have significant disc swelling with surprisingly tolerable headache.
This disconnect matters (and trips up patients repeatedly): headache improvement alone is not a reliable guide to whether the optic nerves are safe. A patient whose headache has improved a great deal may still have active papilloedema and ongoing visual field loss. Ophthalmological monitoring continues independently of how the headache is doing.
Medication overuse headache is a significant complication in IIH. Using simple analgesics or triptans on more than ten to fifteen days per month can cause rebound headache superimposed on the IIH headache, and these become very difficult to distinguish from each other. Neurologist input alongside ophthalmological care is important for patients whose headache management is complex.
Seek Urgent Assessment If You Experience
- A sudden severe headache that is different from your usual IIH headaches, especially the worst headache of your life
- Rapid or sudden loss of vision in one or both eyes
- New double vision or sudden onset sixth nerve palsy
- Visual symptoms markedly worse than your usual transient obscurations
Established IIH patients know their usual symptom pattern. A change from that pattern, particularly involving vision, deserves urgent ophthalmological review rather than watchful waiting. Visual field loss in IIH can progress rapidly in some patients and the window for intervention can be narrow. If in doubt, contact your eye unit the same day.
Frequently Asked Questions About IIH
-
Will I lose my vision from IIH?
Most patients with IIH who are diagnosed and treated appropriately preserve their vision. The risk of permanent visual impairment is real but is largely preventable with regular monitoring and good treatment adherence. Patients at greatest risk are those with severe papilloedema at presentation, significant early visual field loss, and those not followed closely enough for progression to be caught in time. With modern treatment, severe visual loss from IIH is increasingly uncommon.
-
Why does my ophthalmologist keep testing my visual fields when my headache is better?
Because headache improvement and optic nerve safety are not the same thing. They don’t reliably track each other. Papilloedema and visual field loss can progress even when headache is well controlled. The visual field loss in IIH is often peripheral and silent until it’s well established. Visual field testing and OCT are the only ways to know whether treatment is actually protecting your vision. They need to continue regardless of how you feel.
-
Can IIH come back after it has resolved?
Yes. Yes. Recurrence is well documented, and the most common reason is weight regain after initial loss. Patients who achieve remission through weight loss should maintain it to reduce recurrence risk. Any return of characteristic symptoms, including headache, transient visual obscurations, or pulsatile tinnitus, in a patient with a history of IIH should prompt re-investigation rather than reassurance without assessment.
-
Is IIH dangerous during pregnancy?
Yes, it needs careful co-management between ophthalmology, neurology, and obstetrics during pregnancy. The condition can worsen during pregnancy and visual fields must be monitored closely throughout. Acetazolamide is generally avoided in the first trimester due to teratogenicity concerns, though it may be used later in pregnancy when the risk to vision outweighs the risk of the medication. Women with known IIH who are planning a pregnancy should discuss management in advance with their specialist team.
-
Can losing weight really cure IIH?
In many cases, yes. The evidence is clear: sustained, significant weight loss in overweight patients with IIH reduces intracranial pressure and can produce complete remission including resolution of papilloedema and normalisation of visual fields. The IIH Weight Trial showed that weight loss achieved through a very low calorie diet produced improvements in visual field comparable to acetazolamide. Weight loss is genuinely the most powerful treatment available for most IIH patients.
-
What medications can cause or worsen IIH?
Several medications are associated with IIH and should be reviewed at diagnosis. The most important are high-dose vitamin A and retinoids (including isotretinoin for acne), tetracycline antibiotics (including doxycycline and minocycline), recombinant growth hormone, and prolonged corticosteroid use followed by rapid withdrawal. Some hormonal contraceptives have also been implicated, though the evidence is less consistent. Any potentially contributing medication should be reviewed with the prescribing doctor as part of overall management.
If you would like to learn more, the American Academy of Ophthalmology’s overview of idiopathic intracranial hypertension offers a helpful summary of how IIH is diagnosed and managed, including papilledema, visual field testing, imaging, and treatment options.